DRD2/3拮抗剂ONC201联合放疗对胶质母细胞瘤的作用
该研究利用患者来源的胶质母细胞瘤(GBM)细胞系和小鼠模型,测试ONC201联合放疗对GBM自我更新和生存的影响。结果显示ONC201降低自我更新、克隆形成和细胞活力,联合放疗在多种小鼠模型中延长生存,且未增加毒性,机制可能与抑制胶质瘤起始细胞有关。
要点
- ONC201在体外减少GBM细胞自我更新、克隆形成和活力。
- ONC201联合放疗在同系和患者来源原位异种移植小鼠模型中延长生存。
- 联合治疗未增加小鼠模型毒性,支持进一步临床评估。
核心结论
- ONC201联合放疗通过抑制胶质瘤起始细胞提高对GBM的疗效,且在小鼠模型中未增加毒性。
研究设计与样本
- 使用患者来源GBM细胞系和小鼠GBM模型,体外检测自我更新,体内评估生存,并用RNA测序探索耐药机制。
主要发现
- ONC201处理减少GBM细胞自我更新、克隆形成和细胞活力。
- ONC201对放射抵抗GBM细胞有抗肿瘤效应,表现为二级和三级胶质瘤球自我更新减少。
- ONC201联合放疗延长同系和患者来源原位异种移植小鼠模型的生存。
- 联合治疗后转录组分析显示与静息GBM群体、GBM可塑性和GBM干细胞相关的基因表达特征发生改变。
临床怎么用
- 提示DRD2/3拮抗剂ONC201联合放疗可能成为GBM治疗策略,需进一步临床评估。
局限性
- 研究限于体外细胞系和小鼠模型,尚未在患者中验证临床疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the deadliest of all brain cancers in adults. The current standard-of-care is surgery followed by radiotherapy and temozolomide, leading to a median survival time of only 15 months. GBM are organized hierarchically with a small number of glioma-initiating cells (GICs), responsible for therapy resistance and tumor recurrence, suggesting that targeting GICs could improve treatment response. ONC201 is a first-in-class anti-tumor agent with clinical efficacy in some forms of high-grade gliomas. Here we test its efficacy against GBM in combination with radiation. METHODS: Using patient-derived GBM lines and mouse models of GBM we test the effects of radiation and ONC201 on GBM self-renewalin vitro and survivalin vivo.A possible resistance mechanism is investigated using RNA-Sequencing. RESULTS: Treatment of GBM cells with ONC201 reduced self-renewal, clonogenicity and cell viabilityin vitro. ONC201 exhibited anti-tumor effects on radioresistant GBM cells indicated by reduced self-renewal in secondary and tertiary glioma spheres. Combined treatment of ONC201 and radiation prolonged survival in syngeneic and patient-derived orthotopic xenograft mouse models of GBM. Subsequent transcriptome analyses after combined treatment revealed shifts in gene expression signatures related to quiescent GBM populations, GBM plasticity, and GBM stem cells. CONCLUSIONS: Our findings suggest that combined treatment with the DRD2/3 antagonist ONC201 and radiation improves the efficacy of radiation against GBMin vitroandin vivothrough suppression of GICs without increasing toxicity in mouse models of GBM. A clinical assessment of this novel combination therapy against GBM is further warranted.
引用
- He L, Bhat K, Ioannidis A, et al. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. Radiother Oncol. 2021. PMID: 34097975. doi:10.1016/j.radonc.2021.05.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。